NEW YORK (GenomeWeb News) – Quest Diagnostics today reported that its revenues in the first quarter dropped 6 percent year over year as it missed the average analyst estimate on both the top and bottom lines.

For the three months ended March 31, the firm brought in $1.79 billion in revenues, down from $1.91 billion a year ago and short of the $1.86 billion expected by Wall Street.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PLOS this week: genomic analysis of Malaysian tuberculosis strain, database of bat genomes, and more.

An editorial appearing at The Scientist bemoans the high numbers of mitochondrial genome papers and suggests a different path for mitochondrial genome research.

Researchers and drug developers are excited about the potential of CRISPR-Cas9-based therapeutics, the Wall Street Journal reports.

US lawmakers want to develop a new incarnation of the National Children's Study, ScienceInsider reports.